Co-inhibition of TIGIT with anti-TIGIT antibody tiragolumab and anti-PD-L1 antibody atezolizumab restored functional tumour-specific T cells leading to greater ORR and progression-free survival in patients with non-small lung cancer. Here, CD274 is linked to neoplasm.